Multiple studies suggest that the mutation may be associated with poor prognosis in lung cancer.21,22) Notably, in patients with KRAS mutations, the KRAS-Akt pathway might facilitate the motility of neoplastic cells during the early period of carcinogenesis in lung adenocarcinomas and may contribute to their noninvasive expansion along the alveolar septa, leading to tumor cell spreading along the alveolar surfaces. Here, KRAS is linked to lung cancer.